Zenas BioPharma Q2 FY26 net loss widens to $111.5 million; revenue rises to $1 million

Reuters2026/08/13 11:04

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Zenas posted Q2 2026 net loss of $111.5 million, widening from $52.2 million a year earlier.
Revenue was $1 million, swinging from no revenue, tied to a development milestone under its Tenacia agreement for ZB005.
R&D expense climbed to $62.9 million from $43 million, on higher clinical trial, regulatory, and personnel costs.
G&A expense rose to $15.7 million from $12.1 million, reflecting higher headcount and pre-commercialization spending.
FDA accepted obexelimab’s IgG4-RD BLA with a May 27, 2027 PDUFA date; cash and investments totaled $673.9 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608130700PRIMZONEFULLFEED9809447) on August 13, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Zenas BioPharma Q2 FY26 net loss widens to $111.5 million; revenue rises to $1 million

You may also like

Crypto prices